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ANUHYA SHARMA KONDURU 
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ABSTRACT 
Diabetes mellitus is characterized by hyperglycemia, oxidative stress and excessive 
production of intermediary metabolites including methylglyoxal (MGO), a reactive carbonyl. 
MGO can readily interact with proteins, lipids and DNA, and cause an imbalance of the cellular 
antioxidant system leading to carbonyl stress. The effects of MGO can be devastating if the 
targeted molecules are responsible for the maintenance of membrane potentials and ionic 
homeostasis. Here we show that MGO disrupts the vascular isoform of ATP-sensitive K
+
 (KATP) 
channels by acting on the mRNAs of Kir6.1 and SUR2B subunits thereby regulating vascular 
tone. Our results show that the 3’ untranslated region (UTR) of Kir6.1 mRNA and the coding 
region of SUR2B mRNA are targeted by MGO causing a disruption of vascular KATP channels. 
The destabilization of the mRNAs of KATP channel can in turn affect K
+
 homeostasis of vascular 
smooth muscles as well as vascular responses to circulating vasodilators and vasoconstrictors.  
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1.  INTRODUCTION 
1.1 Reactive carbonyl species 
Carbonyl species are compounds containing the (C=O) carbonyl functional group. As 
oxygen atom in the carbonyl group is more electronegative than the carbon atom, it pulls the 
electrons from the carbon atom and thereby increases the polarity of the carbonyl group. The 
carbonyl carbon is electrophilic in nature and readily reacts with nucleophiles. The carbonyls 
methylglyoxal (MGO), glyoxal, acrolein, hydroxyhexenal, hydroxynonenal (HNE) are highly 
reactive compared to other carbonyls produced in the biological system (Ellis, 2007). These 
carbonyls are collectively called reactive carbonyl species (RCS). RCS are more stable than the 
free radicals, and can diffuse over long distances to reach its target molecules (Lesgards et al., 
2011). 
1.2 Carbonyls in pathological conditions 
Diabetes mellitus is a systemic disorder that affects 8.3% of the population in the United 
States (Department of Health and Human Services, 2011). Persistent hyperglycemia in diabetic 
patients causes metabolic alterations, leading to overproduction of a variety of intermediary 
metabolites. One of the metabolites is the reactive α,β-dicarbonyl, MGO which is both an 
aldehyde and a ketone. MGO has been attributed to be responsible for the development and 
progression of diabetes and diabetes associated vascular complications (Bourajjaj et al., 2003) 
like atherosclerosis, ischaemia, hypertension, retinopathy and nephropathy (Brownlee, 2001). All 
of the diabetes associated vascular complications are characterized by a variety of changes in the 
micro and macro vasculatures. Most of these changes are due the impairment of the appropriate 
response of the vasculatures to vascoactive substances, hormones, neurotransmitters, cytokines 
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etc. The changes in the vasculature can be one of the following or a consortium of many. 
Abnormal function of the vasculature and high potential for thrombosis can lead to 
atherosclerosis. Inflammation, presence of high levels of oxidants and stiffening of the 
vasculature and improper expression of surface markers are also markers for vascular 
complications (Creager et al., 2003). In Alzheimer’s disease an increase in the levels of acrolein, 
HNE and acrolein modified proteins have been identified (Lovell et al., 2001). Increased levels 
of HNE and HNE modified proteins have also been identified in hypertension (Asselin et al., 
2006). HNE has also been identified in atherosclerotic plaques (Leonarduzzi et al., 2005). MGO 
is also thought to be present in the amyloid plaques (Kuhla et al., 2005).  
1.3 Production of MGO 
MGO is produced via both enzymatic and non-enzymatic reactions. MGO is mainly 
produced via glucose metabolism, through the transformation of triosephosphate intermediates – 
glyceraldehyde-3-phosphate (GAPDH) and dihydroxy acetone phosphate (DHAP) (Cooper, 
1984; Pompliano et al., 1990; Thornalley, 1990) by methylglyoxal synthase. MGO is also 
formed by the metabolism of aminoacetone or acetone from lipolysis, which is catalyzed by 
semicarbazide-sensitive amine oxidase (SSAO) and acetol monooxygenase (Casazza et al., 1984; 
Lyles and Chalmers, 1992). This conversion can also happen via a non-enzymatic reaction in 
which aminoacetone is converted to MGO in the presence of Fe
+2
 as catalyst (Dutra et al., 2001).  
Additionally MGO is also formed during the cellular metabolic process like protein metabolism 
(Lyles and Chalmers, 1992). Proteins containing L-threonine undergo oxidation in the 
mitochondria to form glycine and acetyl-CoA via the intermediate 2-amino-3-oxobutyrate (Bird 
et al., 1984). In case of diabetes, 2-amino-3-oxobutyrate is driven towards formation of 
aminoacetone, a precursor for MGO production (Kalapos, 2008).  
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All forms of diabetes are associated with hyperglycemia and increase in the levels of 
reactive oxygen species (ROS) like superoxide anion (O2
-
), hydroxyl ion (OH
-
), and non-radical 
reactive species like hydrogen peroxide (H2O2). Increased levels of intracellular oxidants can 
lead to the peroxidation of membrane lipids (Esterbauer et al., 1991), which can lead to the 
generation of carbonyl species like MGO, through a series of oxidative and rearrangement 
reactions (Esterbauer et al., 1982). Reducing sugars can react with the amino groups of Lys and 
Arg residues on proteins to form Schiff’s bases via a Maillard reaction. The Schiff bases can 
undergo a series of rearrangement reactions to form advanced glycation end products (AGEs) 
(Thornalley et al., 1999). Oxidation of the thus formed AGEs  leads to the generation of carbonyl 
species like MGO, glyoxal, acrolein (Thornalley, 2005). Under hyperglycemic conditions 
increased flux through the polyol - fructose pathway is observed which leads to the formation of 
MGO (Desai et al., 2010). 
1.4 Reactivity of MGO 
MGO is highly reactive due to the presence of the ketone group at C2 in addition to the 
aldehyde group at C1. The carbonyl groups are electrophilic and can undergo addition with the 
nucleophilic groups on proteins, DNA, RNA and lipids (Cooper et al., 1987; Marnett et al., 
1985).  
1.4.1 Protein modification by MGO 
The carbonyl groups (aldehyde/ketone) of MGO can react with the amino group (NH4
+
) 
on the amino acids Lys and Arg to form Schiff bases (compounds containing C=N), the 
formation of which are reversible. The Schiff bases can undergo a series of acid or base 
catalyzed isomerization reactions that lead to the formation of Amadori products (rearranged 
Schiff’s base in which the nitrogen in C=N is bound by a hydrogen atom from the adjacent OH-). 
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The Amadori products can further undergo a series of condensation, oxidation in presence of 
metals and dehydration reactions to AGEs (Wautier and Schmidt, 2004). MGO reacts with the 
Arg and Lys residues on proteins to form the AGEs 5-hydro-5-methylimidazolones (Thornalley 
et al., 2003), argypyrimidine (Shipanova et al., 1997) and N
ɛ
-carboxymethyl lysine, N
ɛ
-
carboxyethyl lysine (Ahmed et al., 2002) adducts respectively. Additionally the carbonyl groups 
of MGO can also react with the sulphydryl groups (-SH) on the Cys residues on proteins to form 
glycation adducts (Sato et al., 1980). The protein glycation adducts are stable and thus pose 
problems for the normal functioning of the biological system.  
1.4.2 Modification of nucleotides by MGO 
MGO preferentially reacts with the NH2 groups present on the guanine nucleotides to 
form tricyclic compounds (Vaca et al., 1994). MGO reacts with the deoxyguanidine (dG) 
nucleotides to form 3-(2′-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6-methylimidazo-[2,3-
b]purine-9(8)one and N2-(1-carboxyethyl)-deoxyguanosine (Papoulis et al., 1995; Schneider et 
al., 1998). To differentiate from the MGO derived protein adducts, the MGO adducts formed 
with the nucleotides are called nucleotide AGEs.  
MGO preferentially reacts with the single stranded nucleotides, RNA and denatured 
DNA. This is because the guanine nucleotides in native DNA molecules are protected from the 
electrophilic attack of MGO due to the double stranded structure (Krymkiewicz, 1973). 
1.5 Metabolism of MGO 
 Irrespective of the production pathway, MGO is detoxified and maintained at normal 
levels in the cell by the glyoxalaseI/II system in presence of reduced glutathione (GSH). 
Glyoxalase I enzyme converts the MGO-GSH adducts into S-lactoylglutathione, following 
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which glyoxalase II enzyme converts S-lactoylglutathione into harmless D-lactate and releases 
the GSH (Chang and Wu, 2006) for the next round of detoxification.  
 In addition to the glyoxalase system, several other enzymes exist that facilitate the 
metabolism of MGO to other relatively harmless compounds. MGO contains two functional 
groups that can undergo either oxidation or reduction. MGO is also a substrate for the aldehyde 
dehydrogenase family of enzymes (ALDH2, ALDH3 and ALDH5), which can oxidize MGO 
into carboxylic acids (Vasiliou et al., 2004). This conversion also provides a protective role 
against oxidative stress (Ohsawa et al., 2003) in addition to carbonyl stress. Cytochrome P450 
enzymes also facilitate the oxidation of the toxic aldehydes like MGO to carboxylic acids 
through hydroxylation of C-H bonds (Ellis, 2007). The enzymes aldehyde reductase (AKR 1A) 
and aldose reductase (AKR 1B) belonging to the  family of aldo-keto reductases (AKR) play a 
role in reducing the aldehyde to alcohols, converting MGO to acetol and D-lactaldehyde (Vander 
Jagt et al., 1992). Alcohol dehydrogenase enzymes (ADH) are known to reduce the unsaturated 
double bond in the aldehydes to detoxify the aldehydes into alcohols (Hartley et al., 1995). 
1.6 Carbonyl Stress 
Under pathological conditions the levels of RCS exceed way above the normal levels as a 
consequence of the presence of increased amounts of the precursor molecules like plasma 
glucose, L-threonine, fructose, lipid peroxidation products and oxidants. Additionally in many 
pathological conditions the carbonyl detoxification system is impaired at the DNA or protein 
level (Thornalley, 2003). This leads to an accumulation of RCS, due to a failure in the clearance 
of RCS from the cell. This imbalance in the production and clearance of RCS leads to the 
phenomenon called carbonyl stress. Excess RCS are not only cytotoxic but can also act as 
mediators of oxidative stress and as secondary cytotoxic messengers (Lesgards et al., 2011). 
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Modification of proteins by RCS is more rapid compared to the modifications by its precursor 
glucose (Lo et al., 1994) even when present in low concentrations. MGO and MGO derived 
molecules have been identified as indicators of carbonyl stress in vivo (Baynes and Thorpe, 
1999). 
1.7 MGO toxicity 
MGO can readily react with proteins and lipids leading to disruption of functional 
molecules and can cause structural damages to transporters, ion channels, transcription factors, 
signaling molecules and plasma membranes (Picklo et al., 2002). Double stranded DNA 
continuously opens up and closes throughout its structure thereby creating and closing gaps 
continously. MGO can bind to DNA at such gaps and can form DNA-MGO adducts 
(Krymkiewicz, 1973). These reactions proceed via reactions involving free radicals (Lo et al., 
2006). The guanine residues on DNA and RNA can be targeted by MGO, which can lead to 
abnormalities in replication and transcription processes (Wu, 2006).  
MGO reacts with the proteins to form AGEs/AGE precursor molecules (Thornalley et al., 
1999). AGEs are involved in the pathogenesis associated with vascular complications related to 
many vascular diseases (Rosca et al., 2005). AGE precursors affect the target cells by several 
mechanisms. AGEs react with many intracellular proteins and alter the protein structure and 
function. AGE precursors can modify some of the extracellular matrix components, which can 
react abnormally with the receptors and structural components of the matrix on the cells. AGEs 
on extracellular matrix (ECM) interfere with the normal matrix-matrix and matrix-cell 
interactions. AGE induced crosslinks can alter the structure and function of the intact blood 
vessels by making them less elastic and more permeable (Brownlee, 2001). AGEs primarily 
target the structural components  mainly collagen IV, fibrinogen, myelin, tubulin (Vlassara, 
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1996). Hydroimidazolone adducts formed by MGO can react with Type IV collagen in the 
vascular basement membrane and disrupt the integrin binding sites on the collagen (Vlassara, 
1996). This leads to endothelial shedding and results in excess amounts of circulating endothelial 
cells (ECs). Increase in the circulating ECs is an indication of vascular damage associated with 
diabetes and uremia. MGO or AGE precursors can modify the plasma proteins in the cell to form 
AGEs. AGEs effect the cellular function by binding to specific receptors called receptors for 
advanced glycation end products (RAGE). RAGE are present on ECs, vascular smooth muscle 
cells (VSMCs), cardiac myocytes, macrophages and monocytes (Thornalley, 1998).  Increased 
expression of RAGE on VSMCs and ECs has been observed in diabetes (Schmidt et al., 1999) . 
AGE receptor-ligand interaction induces ROS production and activates NF-κB transcription 
factor causing unwanted changes in the gene expression several cytokines and growth factors 
like TNF-α, TGF-β, GMCSF, pro-inflammatory molecules, cell adhesion molecules molecules 
like VCAM-1, that effects the cell-cell and cell-matrix communication (Brownlee, 2001). 
Glycated proteins are resistant to protein degradation mechanisms and can lead to the 
accumulation of AGEs in local environments (Brownlee, 1995). AGEs increase the levels of 
diacyl glycerol (DAG) which can activate different isoforms of PKC. Activated PKC has been 
shown to inhibit the KATP channel (Yang et al., 2008).   
AGEs act on the –SH groups of antioxidant detoxifying enzymes like glyoxalase I 
(Thornalley, 2003)  and superoxide dismutase (SOD) (Desai and Wu, 2008), glutathione 
reductase (Vander Jagt et al., 1997), to inactivate the enzymes. MGO can lower the levels of 
intracellular antioxidant - GSH leading to an imbalance in the oxidant-antioxidant ratio in the 
cells to cause oxidative stress (Thornalley, 2003). This leads to an overall decrease in the levels 
of functional antioxidant enzymes and leads to an impairment of the ROS and RCS clearance.  
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1.8 Carbonyl stress vs. Oxidative stress 
MGO induced toxicity has been attributed to the presence of free radicals in both MGO 
generation and degradation processes (Kalapos, 2008). The enzymatic formation of 
methylglyoxal from aminoacetone yields H2O2, whereas a non-enzymatic conversion of 
aminoacetone to methylglyoxal releases O2
-
. Enzymatic conversion of acetol to methylglyoxal 
produces H2O2. Auto-oxidation and photolysis of MGO in the presence of OH
-
 has been reported 
to produce acetyl radicals (Nukaya et al., 1993). The ROS produced during MGO production can 
contribute to initiate or elevate cellular oxidative stress in the absence of appropriate 
detoxification systems. Oxidative stress is known to be associated with many cardiovascular 
diseases like diabetes, atherosclerosis, ischaemia, hypertension, aging, retinopathy, Alzheimers, 
end stage renal failure, inflammation (Ellis, 2007). In addition, oxidative stress can also lead to 
the production of several reactive aldehydes and ketones and thus contribute to carbonyl stress. 
Indeed, recent studies have shown that reactive carbonyls, rather than the initial ROS, are 
responsible for diabetic vascular complications (Ellis, 2007). Thus the relation between the 
generation of RCS and ROS is intertwined. The production of one kind of reactive species can 
lead to the generation of the other. 
1.9 Maintenance of the vascular tone 
Vascular tone is regulated by the combined action of several neuronal, hormonal 
mechanisms in addition to the local metabolic state of the cells to maintain homeostasis. 
Disruption of this regulation leads to cellular dysfunction and leads to the progression of severe 
diseases including diabetes associated macrovascular and microvascular complications, 
atherosclerosis, ischemia, hyperemia, shock and hypertension (Gutterman et al., 2005; Webb, 
2003). Blood vessels are made of ECs and smooth muscle cells (SMCs) which maintain the 
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vascular structure and function. The ECs form the blood vessel lumen as they are positioned 
between the circulating blood and the vessel wall. The SMCs are wrapped around the ECs and 
generate the force required to constrict or dilate the blood vessels. Acting on either the vascular 
endothelium, smooth muscle or both, the regulation of vascular tone is achieved by a 
complicated signaling network involving circulating hormones, neurotransmitters and 
metabolites (Liu and Gutterman, 2009).  
1.10 Effect of MGO on the vasculature 
Increased levels of MGO have been observed in patients with vascular diseases. Most of 
the vascular diseases are associated with initial changes in the vascular permeability followed by 
structural remodeling of the vasculature. Patients with Type-I diabetes mellitus have a 5-6 fold 
increase in plasma levels of MGO whereas patients with Type-II diabetes mellitus, have a 2-3 
fold increase (McLellan et al., 1994). Previous studies have shown that plasma MGO levels 
range from 14.2 µM to 33.6 µM in healthy rats (Wang et al., 2004). Several orders of elevation 
in the MGO levels are expected to take place with persistent hyperglycemia (Chang and Wu, 
2006). The MGO levels may be even higher in local tissues than in the plasma as a result of 
immediate release from cells. Indeed, the MGO levels are as high as 300 µM when measured in 
cultured mammalian cells (Chaplen et al., 1998). The exact mechanism by which MGO alters the 
structure and function of the vasculature is unknown. Impaired endothelial dependent 
vasorelaxation and an increase in the contractility of the vasculature have been observed in 
human and animal models for hypertension. Dysfunction of the vascular tone is also associated 
with diabetes, which is characterized by altered metabolic states like hyperglycemia, excess fatty 
acid availability and insulin resistance. Hyperglycemia causes a decrease in the endothelial nitric 
oxide (NO) production, and also increases the chances of VSMC proliferation. Being highly 
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reactive, MGO can react with the –SH and NH4
+ 
groups on the proteins present on the VSMCs 
and ECs on the walls of the blood vessels, thereby interfering with the normal functioning of the 
vasculature. Altered Ca
+2 
homeostasis has been observed in VSMCs and ECs in animal models 
treated with MGO (Vasdev et al., 1998). Despite the accumulating evidence for the adverse 
effects of MGO, the mechanisms and the molecular targets through which MGO regulates the 
function of VSMs remain to be demonstrated. 
1.11 Control of vascular tone 
VSMCs are excitable in nature. Membrane potentials of VSMCs determine the muscle 
contractility (Wray et al., 2005). KATP channels are present on the plasma membranes of SMCs. 
Closure of KATP channels in response to changes in metabolic state causes membrane 
depolarization. Membrane depolarization leads to the activation of voltage-dependent Ca
+2
 
channels (VDCC) raising cytosolic Ca
+2
 levels. The increase in intracellular Ca
+2
 induces the 
release of more Ca
+2
. Intracellular Ca
+2
 binds to calmodulin to form a Ca
+2
 – calmodulin 
complex. This complex binds to myosin light-chain kinase (MLCK) and activates it. Activated 
MLCK, in turn phosphorylates the myosin light-chain (Herring et al., 2006), which interacts with 
the actin and causes smooth muscle contraction (Wray et al., 2005). On the contrary, 
hyperpolarization reduces the activity of the VDCC, lowers the intracellular Ca
+2
 levels, and 
eventually results in the relaxation of vascular SMCs. Owing to its critical role in maintaining 
vascular tone, KATP channel is modulated by a number of vasoactive substances and metabolites. 
1.12 KATP channels 
ATP sensitive K
+ 
channels (KATP) channels are present on excitable cells like cardiac 
myocytes, pancreatic β cells, skeletal muscle, vascular SMCs and neurons. Functional KATP 
channels are octamers made up of two different types of subunits, four Kir6.x (inwardly 
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rectifying potassium channel) and four sulphonyl urea receptor (SURx) subunits that belong to 
the ABC family of transporters. The KATP channel pore is formed by the Kir6.x (Kir6.1 or 
Kir6.2) subunits. The Kir6.x subunits consist of two transmembrane domains (TMDs) linked by 
a pore loop. The SURx subunit exists in two isoforms SUR1 and SUR2. Each SUR isoform has 
different splice variants. The SURx subunit consists of three membrane spanning domains 
(MSD) and two nucleotide binding domains (NBDs). ATP binds to the two NBDs in the SUR 
subunit and is hydrolyzed. ATP hydrolysis by NBD generates the energy required for the 
conformational change of the MSD domains, which further produce the force required for the 
gating of the pore forming Kir subunit. KATP channels are inhibited by ATP and activated by 
nucleotide diphosphate (NDP) e.g., MgADP. By sensing the ATP and NDP levels, KATP 
channels couple cellular metabolism to membrane excitability. Different possible combinations 
of the Kir6.x and SURx subunits exist, giving rise to a variety of KATP channels with different 
physiological roles. Kir6.2/SUR2A channels are observed in cardiac and skeletal muscle whereas 
Kir6.1/SUR2B channels are found in VSMCs. Disruption of the KATP channels can have severe 
consequences as knockout of the Kir6.1 gene in mice leads to coronary vasospasm and sudden 
death (Chutkow et al., 2002; Miki et al., 2002). In diabetic patients, the vascular response to 
KATP channel openers is impaired, resulting in a defect in vasodilation (Desai et al., 2010; Miura 
et al., 2003). 
1.13 Cell’s response to stress conditions 
A cell responds to stress by regulating several key components of the cellular machinery. 
Cells respond to stimuli like extreme temperatures, oxidants, inflammation, and exposure to 
endotoxins, harmful metabolites and genotoxins by implementing a series of adaptive responses 
known as the cellular stress responses. The main player in the cellular stress response is the 
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regulation of expression levels of a number of genes. The gene expression can be regulated at the 
transcriptional level or by post-transcriptional regulatory mechanisms affecting the stability of 
and translational efficiency of the mRNA (Brennan and Steitz, 2001; Fan et al., 2002). Although 
cells have mechanisms for the regulation of the mRNA turnover rate to meet their functional 
needs, transcriptional inhibition and mRNA instability can have severe consequences on cellular 
function and survival. 
1.14 MGO causes a decrease in the expression of vascular KATP channels 
The detrimental effect of MGO has been observed in a range of pathologies. Previously 
studies were carried out to investigate the role of MGO in the development of vascular 
complications. Experiments were carried out to test the effect of endogenously produced 
metabolite MGO on the expression levels of vascular KATP channels. qPCR experiments were 
carried out to study the levels of Kir6.1 and SUR2B mRNA in MGO treated A-10 smooth 
muscle cell line (which endogenously express Kir6.1/SUR2B vascular isoform of the KATP 
channels) (Shi et al., 2010). A-10 cells were treated with varying concentrations of MGO for a 
12 h period. Following MGO treatment the total RNA was extracted  and was subsequently 
analyzed by regular PCR and qPCR techniques. 
Regular PCR analysis showed a clear decrease in the levels of Kir6.1 and SUR2B 
mRNAs following a 300 µM MGO treatment. Higher doses of MGO (1 mM) lead to nearly a 
total loss in the levels of Kir6.1 and SUR2B mRNAs. However, the mRNA levels of the internal 
control GAPDH did not show a significant change in response to similar MGO treatments (Fig. 
1A). This suggests that the effect of MGO on the mRNAs is not global but is specific only to 
Kir6.1 and SUR2B mRNAs. qPCR analysis following MGO treatment showed that the levels of 
Kir6.1 and SUR2B mRNAs decreased in a concentration dependent manner. The IC50 for Kir6.1 
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and SUR2B mRNAs was found to be 350 μM and 290 μM respectively (Fig. 1B and C). The 
effect mediated by MGO on the levels of Kir6.1 and SUR2B mRNAs was also found to be time-
dependent. The levels of Kir6.1 and SUR2B mRNAs followed a time dependent decrease in 
response to a 500 μM MGO treatment. The time constant for the mRNA reduction was 1.15 h for 
Kir6.1 and 0.33 h for SUR2B mRNAs respectively (Fig. 1D and E). (Yang et al., 2011 in review) 
 
 
 
 
 
 
 
 
 
 
Yang Y, Konduru AS, Trower TC, Shi W, Cui N, Jiang C; J.Biol Chem. (in review) 
Figure 1. Prolonged exposure to MGO causes a decrease in the levels of Kir6.1 and SUR2B mRNAs              
A. Regular PCR analysis showed a decrease in the levels of Kir6.1 and SUR2B mRNAs on exposure to 
300 μM and 1 mM MGO treatment. The levels of GAPDH mRNA showed no detectable change. CTL, 
control. B-E. qPCR analysis of Kir6.1 and SUR2B mRNA following MGO treatment. B, C. Reduction in 
the levels of Kir6.1 and SUR2B mRNA after a 12 h treatment with 300 μM and 1 mM MGO. Kir6.1 IC50 
= 350 μM and SUR2B IC50 = 290 μM. D, E. MGO mediated decrease in the levels of Kir6.1 and SUR2B 
mRNAs followed a time-dependence with a time constant τ, 1.15 h for Kir6.1 and 0.33 h for SUR2B. 
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1.15 MGO causes a suppression of the vascular KATP channel currents 
 
 
 
 
 
 
 
 
 
 
Yang Y, Konduru AS, Trower TC, Shi W, Cui N, Jiang C; J.Biol Chem. (in review) 
Figure 2. Prolonged treatments with MGO led to vascular KATP channel inhibition  
A. KATP channel current activated by pinacidil. B, C. Reduction in the pinacidil-induced KATP channel 
current in response to 1 mM MGO exposure for 3 h and 22 h respectively. D. Summary of the 
quantitation of pinacidil-induced vascular KATP channel currents in control and MGO treatment (22 h, 1 
mM). E. Summary of the quantitation of KATP channel currents described as a function of time, with the 
time constant 3 h.  
A reduction in the levels of Kir6.1 and SUR2B mRNAs has a major impact on the overall 
function of the vascular KATP channels. This was determined by the study of whole cell currents 
in HEK293 cells in which the vascular Kir6.1/SUR2B channel was heterologously expressed. 
The KATP channel currents were activated by an exposure to pinacidil (Pin, KATP channel opener) 
(Fig. 2A) that were suppressed by glibenclamide (Glib, KATP channel blocker), followed by an 
exposure to 1 mM MGO for 3 h (Fig. 2B). Increasing the MGO exposure time to 22 h nearly 
abolished the KATP channel currents (Fig. 2C). Quantitation of the KATP channel currents after a 1 
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mM MGO treatment for 22 h showed a ~90% reduction with a 3 h time constant (Fig. 2D and E) 
which suggests a functional significance of the effect of MGO on the KATP channel activity 
(Yang et al., 2011 in review). 
 
1.16 Inhibition of transcription vs. mRNA destabilization 
To determine if the decrease in the levels of Kir6.1 and SUR2B mRNAs was due to 
transcriptional inhibition or mRNA instability further experiments were carried out. A-10 smooth 
muscle cells with actinomycin D (AcD), a transcriptional inhibitor for different time periods. 
Subsequent PCR analysis showed that the AcD treatment alone did not cause a decrease in the 
levels of Kir6.1 and SUR2B mRNAs. When MGO (300 µM) and AcD (5 µg/ml) were applied 
together, a decrease in the mRNA levels of both Kir6.1 and SUR2B (but not GAPDH) was 
observed. This effect was similar to the effect shown by MGO treatment alone on Kir6.1 and 
SUR2B mRNAs. This suggests that MGO mediated decrease in the levels of Kir6.1 and SUR2B 
mRNAs is not due to suppression of transcription but due to the direct targeting of the KATP 
channel mRNAs by MGO (Fig. 3A). (Yang et al., 2011 in review). 
 Quantitation of the mRNA levels of Kir6.1 showed a decrease in the levels of Kir6.1 
mRNA in response to AcD alone whereas a greater extent of reduction was observed following 
MGO alone treatment (Fig. 3B). The levels of SUR2B mRNA marginally decreased with AcD 
alone whereas a MGO alone treatment caused a dramatic decrease in the levels of SUR2B 
mRNA (Fig.3D). However the combined treatment of AcD and MGO did not enhance the 
reduction kinetics of Kir6.1 and SUR2B mRNAs compared with MGO treatment alone (Fig. 3C 
and E) suggesting that the decrease in the levels of Kir6.1 mRNA is due to mRNA instability 
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mediated by the action of MGO but not as a consequence of transcriptional inhibition. (Yang et 
al., 2011 in review). 
 
 
 
 
 
 
 
 
 
 
 
 
Yang Y, Konduru AS, Trower TC, Shi W, Cui N, Jiang C; J.Biol Chem. (in review) 
Figure 3. Inhibition of transcription vs. mRNA destabilization 
Inhibition of transcription vs. mRNA destabilization causing a reduction in the levels of Kir6.1 and 
SUR2B mRNAs. A, Gel images of the reverse transcribed PCR products of GAPDH, Kir6.1 and SUR2B 
mRNAs from A10 cells treated with AcD (A), AcD and MGO (AM) and MGO alone (M) for different 
time periods (1, 3 and 6 h, respectively) denoted as a numerical following each treatment condition. CTL, 
control. B-E. qPCR analysis of Kir6.1 and SUR2B mRNAs following AcD, MGO and combined 
treatment of AcD and MGO (AM) at different time points. 
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1.17 mRNA stability 
 The stability of mRNA has a great impact on the response of the cell to a particular 
stimulus. The mRNA turnover rate can influence the overall protein levels in the cell. The 
stability of the mRNA is dependent on cis-stability elements present on the mRNA and also 
other trans-acting factors. These stability determinants can determine the stability of the mRNA 
by acting in unison with each other or by acting independently of the other. The cis-stability 
determinants identified on the mRNA are the 5’ – guanosine cap, 5’ untranslated region (UTR), 
open reading frame destabilizing sequences, 3’UTR and a stretch of adenosine residues - poly 
(A) tail.  
The 5’guanosine cap present at the 5’end provides resistance to the mRNA from general 
ribonucleases. This resistance is due to the presence of 5’–5’ phosphodiester bond. The removal 
of the 5’guanosine cap, will make the mRNA vulnerable to the 5’–3’ exoribonucleases or 
endoribonucleases. The 5’ UTR sequence also determines the translational efficiency of the 
mRNA. If the mRNA is bound by ribosomes, and is being translated, the stability of the mRNA 
increases. In other words, actively translated mRNA is more stable compared to the ones that are 
not being translated. In addition the 5’ UTR can have one or more internal loops that prevent the 
advancing ribosome to move beyond the loop. The coding region of the mRNA has been 
identified to have stability determining sequences. c-fos mRNA has been identified to have 
destabilizing sequences in the open reading frame (Shyu et al., 1991). These destabilizing 
sequences are purine rich sequences and have been identified as targets for at least two cellular 
proteins. The binding of the cellular proteins to the purine rich sequence initiates mRNA 
degradation (Chen et al., 1992).  
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The 3’UTR of the mRNAs has been long studied for their role in determining the stability 
of the mRNAs. The sequences in the 3’UTR’s of the mRNAs can form stem loops that prevent 
them from being regulated normally. For example the histone mRNA has a 6 bp stem at the near 
end of the 3’ terminal followed a stretch of poly (A). This stem loop was identified to be 
essential in rendering the histone mRNA stable. It is also possible that some binding proteins 
might be binding the histone mRNA at the stem loop and thereby causing the stability of the 
mRNA (Ross, 1995). Conserved stability determining sequences have been identified in the 3’ 
UTRs of different mRNAs. The well-studied stability sequences in the 3’UTRs are the iron 
responsive element (IRE) present on the iron transporting transferrin mRNA and the stretch of 
adenylate and uridylate residus (AURE), AUUUA pentamer present in multiple repeats on the 
mRNAs of cytokines, growth factors and lymphokines. Owing to their presence on the mRNAs 
coding for important proteins in the cellular function, AUREs are considered important in 
determining the stability of the mRNAs. The 3’UTR of the c-fos mRNA was identified to have 
an AURE. When the 3’UTR of the c-fos mRNA was replaced with the 3’UTR of v-fos mRNA, 
there was an accumulation of the c-fos mRNAs following serum stimulation, whereas the c-fos 
mRNA levels dropped significantly when the 3’UTR of c-fos was placed downstream of the 
coding region of c-fos indicating that the AURE containing 3’UTR of c-fos mRNA was 
responsible for determining the stability of c-fos mRNA. Additionally the AURE can also 
function as stabilizing signals in many mRNAs. Many cytoplasmic and nuclear proteins have 
been identified to bind to the AUREs of the mRNAs to influence the stability of the mRNAs 
(Brennan and Steitz, 2001).  
The poly (A) tail of the mRNA has been widely known for conferring stability to the 
mRNA. Poly (A) tails present at the end of the mRNA was initially thought to give protection to 
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the 3’ terminus of the mRNA from ribonucleases. Deadenylation is the first step in initiating 
mRNA degradation from the 3’terminus. Poly (A) tails are specifically bound by Poly (A) 
binding proteins (PABP) that protect the mRNA from deadenylation. In the absence of the poly 
(A) tail the half lived of mRNAs have been observed to be significantly reduced. It has also been 
determined that poly (A) tails increases the translational efficiency of the mRNA by interacting 
with the translation initiation and elongation factors docked at the 5’ terminus of the mRNA. The 
stability of the mRNA increases, when the mRNA is actively transcribed. Thus in the absence of 
poly (A) tail the translational efficiency would be compromised leading to a decrease in the 
stability of the mRNA (Ross, 1995). 
In addition to the cis-stability determinants present on the mRNA, several trans-acting 
factors like ions, growth factors, hormones, metabolites can also affect the stability of the mRNA 
by binding to the cis-stability determinants (Sachs, 1993).  
1.18 Significance 
Although MGO is known to be a major player in vascular complications and vascular 
inflammation state, its vascular targets and mechanisms of action are still unclear. The 
membrane proteins responsible for maintaining the contractility, membrane potentials and 
membrane properties of the ECs and VSMCs can be regulated by MGO. The vascular KATP 
channel is a potentially important target of MGO in vasculatures. Disruption of functional KATP 
channels will lead to abnormalities in cellular excitability, VSM contraction and impairment of 
vascular responses to vasoconstrictors and vasodilators. Therefore, we performed these studies to 
test the hypothesis that MGO affects the function of vascular KATP channels by destabilization of 
Kir6.1 and SUR2B mRNAs because MGO is known to preferentially bind to and react with 
single stranded nucleotides. Our results showed that MGO treatment caused disruption of both 
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Kir6.1 and SUR2B mRNAs through two distinct mechanisms. Such an effect is likely to impair 
membrane potentials and K
+
 homeostasis of VSMs thereby causing vascular dysfunction, seen in 
many vascular diseases. Membrane potential appears to be one of the mechanisms (Liu and 
Gutterman, 2002) that can lead to a disruption of the cellular homeostasis. Depolarization can 
open the voltage-activated Ca
2+
 channels leading to Ca
2+
 influx (Anzai et al., 2000; Wray et al., 
2005). Since K
+
 channels are the primary regulators of membrane potentials, inhibition of the K
+
 
channels results in depolarization and an elevation in intracellular Ca
2+
 (Cook et al., 1988). Since 
several NADPH oxidases for ROS production are stimulated by elevated intracellular Ca
2+
 
(Brandes et al., 2010; Guzik et al., 2008; Hink et al., 2001; Zhang et al., 2008), and since RCS 
and ROS share the antioxidant detoxification systems, sustained depolarization may augment the 
production of these reactive species and aggravate oxidative/carbonyl stress. Thus the 
understanding of the regulation of vascular tone will have a strong influence on designing 
treatments for the vascular diseases. 
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Figure 4. Working hypothesis summarizing the effect of MGO on cellular homeostasis 
Hyperglycemia leads to the production of MGO. MGO causes a reduction in the expression levels of 
vascular KATP channels by causing mRNA instability of Kir6.1 and SUR2B mRNAs. Loss of functional 
KATP channels causes depolarization of the membrane potential, which in turn activates voltage dependent 
calcium channels (VDCC). Activated VDCC leads to an influx of Ca
+2
 into the cytosol. Increased 
cytosolic Ca
+2
 activates the Ca
+2
 dependent NADPH oxidase (NOX), which aids in the production of ROS 
from the mitochondria. ROS produced can further modulate the KATP channels and thereby augment the 
existing carbonyl and oxidative stress. Increased cytosolic Ca
+2
 can also lead to abnormal SMC 
contractility. Glucose is transported into the cell by the GLUT I, glucose transporter.  
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2.  MATERIALS AND METHODS 
2.1 Genomic DNA isolation 
Sprague Dawley rat (Jackson lab) tail tissue was used for isolating the genomic DNA 
using the DNeasy Blood and Tissue kit (Qiagen) following manufacturer’s protocol.  
2.2 Amplification of the 3’ UTR’s of Kir6.1 and SUR2 mRNA 
Primer pairs with a 5’–XhoI overhang for the 3’ UTRs of Kir6.1/SUR2 genes were 
designed based on the conserved sequences from rat genomic sequence (Accession 
no.AC_000072.1). PCR was performed in a 20 µl reaction containing 1 µg of isolated genomic 
DNA, 0.75 mM dNTPs, 2.5 µl DMSO, Pfu ultra buffer at final concentration of 1X, 25 nM of 
primer mixture, 1 µl of Pfu ultra DNA polymerase using Mastercycler (Eppendorf  Pro S) with 
an initial denaturation period of 95 °C for 2 min, followed by 36 cycles of denaturation at 95 °C 
for 50 s, annealing at 60 °C for 45 sec, and extension at 72 °C for 2 min, with a final elongation 
at 72 °C for 10 min. The PCR products were analyzed on a 2% agarose gel.  
Table 1: List of primers for amplification of the 3’UTRs of Kir6.1 and SUR2B mRNAs 
Target 
gene 
Accession   
No. 
                      Primer sequence                              Amplicon  
                             length (bp) 
    
Kir6.1 NM_017099.3  Fw: ACCGCTCGAGCCTCCATCCGGAGGAATAAC 
 Re: ACCGCTCGAGCGTCTTCACAAGACTCCCACAC 
 
  1000 
SUR2 NM_013040.2 Fw: ACCGCTCGAGCGCTGACCTGGTCATTGTGATG     
Re:  ACCGCTCGAGCGCAGGTGAATCCTACCGATAC 
 
                                         
2600 
    
Note: Primers were designed to include the ACCGCTCGAG overhang.  Xho I consensus sequence is 
underlined. 
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2.3 pmirGLO luciferase reporter vector 
The pmirGLO expression vector (Promega) was designed to quantitatively evaluate the 
effect endogenously present or exogenously introduced compounds/factors on a specific gene. 
The vector backbone includes a firefly luciferase gene (luc2) under the control of PGK promoter, 
a multiple cloning site (MCS) downstream of luc2. Additionally the vector contains a renilla 
(hRluc-neo) gene under the control of SV40 promoter. The gene of interest to be studied for 
targeting by miRNAs or other compounds is cloned downstream of luc2 gene. luc2 serves as a 
primary reporter gene, a decrease in the firefly luciferase expression indicates that the gene 
cloned into the reporter vector is targeted by compound/factor under study. hRluc-neo gene 
serves as a control reporter for normalization process. 
2.4 Cloning of the 3’UTRs of Kir6.1 and SUR2B mRNA to pmirGLO luciferase reporter 
vector 
The pmirGLO expression was digested with XhoI restriction enzyme (restriction site 
located downstream of the firefly - luc2 gene) and gel purified with QIAquick gel extraction kit 
(Qiagen) according to the manufacturer’s instructions. The appropriate PCR products for 3’UTR 
of Kir6.1 and SUR2B were purified using the QIAquick PCR purification kit (Qiagen). The 
purified fragments were digested with XhoI enzyme followed by purification of the digested 
fragments. Ligation was performed in a 10 µl volume, 50 ng of digested vector and 300 ng of 
digested fragment were incubated with 400 U of T4 DNA ligase (M0202S, NEB) for 16 h at 16 
°C. The ligated products were transformed into XL1-blue competent cells (Agilent) for 
amplification and the amplified DNA was obtained through plasmid Mini-preparation (Qiagen). 
The constructs were confirmed by DNA sequence analysis. 
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2.5 Cell culture  
Rat vascular smooth muscle cells (A-10, CRL-1476, ATCC, Manassas, VA) were 
cultured as a monolayer and grown to 80-90% confluence in a 35 mm petri dish in 
DMEM/10%FBS in a humidified 5% CO2 atmosphere at 37 °C. 
2.6 Transfection of A-10 cells and MGO treatment 
A 35 mm petri dish of cells was transfected with 1 µg Kir6.1 or SUR2B 3’UTR 
containing pmirGLO luciferase reporter vector using Fugene 6 transfection reagent (Roche 
Applied Science, Indianapolis, IN). The cells were dissociated with trypsin (0.25%) after 8-12 h 
of transfection and were seeded into 96-well plate for further growth. MGO treatment (in 
triplicates) was performed after 18-24h. The cells were treated with 75 μl of 10, 30, 100 and 300 
µM MGO freshly prepared in DMEM/10%FBS for 5 h following which luciferase reporter assay 
was performed.  
2.7 Luciferase assay  
Luciferase reporter assay was performed using the Dual-Glo luciferase assay system 
(Promega), 5 h after the MGO treatment. Briefly, a 75 μl of Dual-Glo substrate equal to the 
volume of the MGO containing culture medium was added to each well and mixed. The firefly 
luminescence was measured using a luminometer (Model 1420 Victor3V, Perkin Elemer, 
Waltham, MA) after a 15-20 min incubation period. After obtaining the firefly luciferase 
reading, 75 μl of Dual Glo Stop & Glo reagent equal to the volume of original culture medium 
was added to each well and the renilla luminescence was measured after 15-20 min. The ratio of 
firefly: renilla luciferase was calculated for each well. The sample well ratio was normalized to 
the control well ratio. 
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2.8 In vitro transcription of Kir6.1 and SUR2B genes 
 cDNA sequences of rat Kir6.1 (GenBank
TM
 No. D42145) and mouse SUR2B 
(GenBank
TM
 No. D86038, mRNA isoform NM_011511) were previously cloned into pcDNA 
3.1cloning vector. Linear template DNA required for in vitro transcription experiments was 
obtained by using a restriction site downstream of the cDNA insert on the pcDNA 3.1. The in 
vitro transcription reactions were performed in RNase free environment with MEGAscript T7 
high yield transcription kit (Ambion). For the in vitro transcription reaction, 1 µg of linearized 
template DNA was incubated with 8 µl of the NTP mixture, 2 µl of 10X reaction buffer and 2 µl 
of T7 enzyme mix in a 20 µl reaction at 37 °C for 4 h. The in vitro transcribed RNA was 
recovered by adding 30 µl of Lithium chloride precipitation solution to the in vitro transcription 
reaction mixture and chilled at -20 °C for 4 h. The RNA was pelleted by centrifugation at 4 °C 
for 15 min at 13,000 rpm. The RNA pellet was washed once with 70% ethanol, re-centrifuged 
and the supernatant was discarded. The RNA pellet was dissolved in appropriate volume of 
RNase free H2O. 
2.9 Exposure of in vitro transcribed Kir6.1 or SUR2B mRNA to MGO 
MGO was diluted to the required concentrations in RNase free H2O from a 5.5 M stock 
solution. For the MGO treatment, 2 µg of RNA was treated with 10 µl of MGO (100, 300 and 
600 µM) at 37 °C for 6, 18 or 24 h time periods. 
2.10 Determination of the effect of MGO on Kir6.1 or SUR2B mRNA 
After MGO treatment, 95% formamide containing gel loading buffer was added to the 
MGO + RNA mixture and heat denatured at 65 °C for 45 min followed by chilling on ice. The 
denatured RNA was resolved on a 1.5% agarose gel and visualized with ethidium bromide under 
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UV-fluorescence. The RNA band intensity on the gel was determined by densitometry analysis 
using ImageJ (Abramoff, 2004). 
2.11 Data Analysis 
Data are presented as the mean ± S.E. Differences in means tested with Student’s t test or 
analysis of variance (ANOVA) and were accepted as significant if P ≤ 0.05. 
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3. SPECIFIC AIM 
To demonstrate that MGO exposure causes a disruption of the mRNAs of Kir6.1 and 
SUR2B subunits of the vascular isoform of the KATP channels, leading to impairment of function 
K+ currents.  
This aim was addressed by a series of studies. The 3’ UTR of mRNA is considered to be 
a major determinant of the stability of the mRNA. The 3’ UTRs of Kir6.1 and SUR2B mRNAs 
were amplified from the respective genomic DNA and cloned to a luciferase reporter vector 
(pmirGLO) to study the effect of MGO on the 3’ UTRs of Kir6.1 and SUR2B mRNAs. In 
addition to the 3’ UTR, the coding region and 5’ UTR of the mRNA are also known to contribute 
to the stability of the mRNA. The mRNAs of Kir6.1 and SUR2B subunits of the vascular KATP 
channel were synthesized by in vitro transcription reactions. The in vitro synthesized mRNAs 
were treated with varying concentrations of MGO and the effect of MGO on the mRNAs of 
Kir6.1 and SUR2B was determined by resolving the MGO treated mRNAs with gel 
electrophoresis and the mRNA bands were visualized under UV-fluorescence. The variation in 
the mRNA bands of MGO treated and non-treated samples was quantified using ImageJ, an 
image processing program. 
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4.  RESULTS 
4.1 MGO acts on the 3’UTR of KATP channel mRNAs 
The stability of a mRNA largely relies on its 3’ UTR (Ross, 1995). To study the effect of 
MGO on the 3’ UTR of Kir6.1 and SUR2B mRNAs, a luciferase reporter vector was used. The 
3’UTRs of Kir6.1 and SUR2B were cloned into the pmirGLO luciferase vector and the A-10 
cells were transfected with Kir6.1 or SUR2B 3’UTR containing luciferase vector. The effect of 
MGO on the luciferase expression in the transfected cells was determined with Dual-Glo 
luciferase assay system, 5 h after MGO (10, 30, 100 and 300 µM) treatment. 
A-10 cells transfected with Kir6.1-3’UTR containing luciferase vector, showed a 
concentration-dependent reduction in the luciferase reporter signal (Fig. 5A). A treatment with 
300 µM MGO led to a maximum decrease in the luciferase activity in the A-10 cells by 28.8 ± 
5.3% (P < 0.001; n = 5) compared with the control. The difference in the luciferase activity 
observed in the cells treated with MGO from that of the control luciferase activity was 
statistically significant.  A decrease in the luciferase activity by 15.2 ± 2.9% (P < 0.05; n = 5) 
and 4.5 ± 3.5% (n = 4) was observed in A-10 cells treated with 100 μM and 10 µM MGO, 
respectively.  
In contrast, A-10 cells transfected with SUR2B-3’UTR containing luciferase vector did not 
show a similar response to the same set of MGO treatments. The decrease in the luciferase 
activity in response to MGO treatment was not statistically significant (Fig. 5B).  
Therefore, it is likely that MGO acts on the 3’UTR of Kir6.1 mRNA causing its instability 
while MGO may mediate its effect on SUR2B mRNA stability via a different mechanism 
instead. 
29 
 
 
 
 
       
 
 
 
 
 
 
 
 
Figure 5. MGO acts on the 3’UTRs of KATP channel mRNAs 
 A-10 cells transfected with Kir6.1-3’UTR or SUR2B-3’UTR containing luciferase reporter vector 
(pmirGLO) were treated with different concentrations of MGO respectively and the luciferase gene 
expression from the reporter vector was measured after 5 h. The ratio of firefly (experimental reporter) : 
renilla (control reporter) luciferase was calculated for each well. The sample well ratio was normalized to 
the control well ratio and is represented on the Y- axis as the amount of luciferase activity in response to 
different MGO treatments along with the control. A. Summary of the effect of different concentrations 
(10 μM, 100 μM and 300 μM) of MGO on the luciferase activity of Kir6.1-3’UTR containing luciferase 
reporter vector.  B. Summary of the effect of different concentrations (30, 100 and 300 μM) of MGO on 
the luciferase activity of SUR2B-3’UTR containing luciferase reporter vector. *, P < 0.05; ***, P < 0.001; 
n = 4 experiments.  
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4.2 MGO suppresses the activity of KATP channels by directly acting on regions other than 
the 3’UTRs on Kir6.1 and SUR2B subunit mRNAs 
Since MGO has been shown to interact directly with nucleic acids (Krymkiewicz, 1973) to 
form adducts, we tested the possibility that the coding sequences of the Kir6.1/SUR2B mRNA 
are targeted by MGO, leading to mRNA degradation. Kir6.1 and SUR2B mRNAs synthesized by 
in vitro transcription reactions were then treated with 100, 300 and 600 μM MGO for 18 h time 
period. The change in the mRNA levels of Kir6.1 and SUR2B following MGO treatment was 
resolved by gel electrophoresis and visualized with ethidium bromide under UV-fluorescence.  
Obvious reduction in the band density of SUR2B mRNA was seen with 300 µM MGO 
treatments, and the decrease in the SUR2B mRNA band was more prominent with 600 µM 
MGO treatment (Fig. 6B top panel). MGO mediated mRNA instability may also result in a 
reduction in the size of the mRNA. Thus, we elongated the image obtained from UV-
fluorescence in a vertical orientation to determine if there is any difference in the migration 
distance of MGO treated mRNA samples compared with the control. This shows that SUR2B 
mRNA treated with 600 µM MGO migrated a slightly longer distance compared with that of 
control mRNA (Fig. 6B bottom panel) and hence the mRNA band lay lower on the gel with 
respect to the control band. This indicates that SUR2B mRNA may be degraded upon MGO 
treatment and thus resulted in a band slightly smaller in size compared with the control.  
Similar experiments were also performed on in vitro transcribed Kir6.1 mRNA. Kir6.1 
mRNA treated with increasing doses of MGO does not show a significant change in the RNA 
levels compared with the control (Fig. 6A) 
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Figure 6. MGO suppresses the activity of KATP channels by directly acting on regions other than the 
3’UTRs on Kir6.1 and SUR2B subunit mRNAs 
Kir6.1 and SUR2B mRNAs were synthesized by in vitro transcription reaction and were treated with 
different concentrations of MGO. A, B. (top panel) Gel image of Kir6.1 and SUR2B mRNAs treated with 
100 µM, 300 µM and 600 µM MGO respectively, along with untreated mRNA, control (CTL) for 18 h 
obtained from UV – fluorescence. (bottom panel) Vertical elongation images of Kir6.1 and SUR2B gel 
images from the corresponding top panels. The dashed line represents the position of the band from the 
control sample, at which the mRNA bands were analyzed for change in migration distance and density. 
The RNA band sizes on the RNA marker are labeled. 
 
Taken together these results suggest that MGO acts on the mRNAs of SUR2B subunit at 
regions other than the 3’ UTR and causes a decrease in the SUR2B mRNA levels, whereas a 
significant decrease in mRNA levels of Kir6.1 subunit was not observed. 
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4.3 MGO mediates dose dependent decrease in the levels of SUR2B mRNA 
The decrease in the mRNA levels of SUR2B following MGO treatment was noted if the 
density of the mRNA bands from MGO treated samples decreased compared with the control 
sample following gel electrophoresis and visualization with UV- fluorescence. The change in the 
mRNA band density in MGO treated mRNA samples compared with the control sample was 
quantified using by densitometry analysis of the RNA bands using ImageJ image processing 
program.SUR2B mRNA was treated with increasing concentrations (100, 300 and 600 μM 
MGO) for different time points.  
 Following a 6 h MGO exposure a marginal decrease in the levels of SUR2B mRNA band 
density was observed in response to increasing concentrations of MGO (Fig. 7A). A decrease in 
the band density by 4.6 ± 0.8% (n = 4) was observed with 100 μM MGO treatment. A further 
increase in the MGO concentration to 300 and 600 μM, lead to a decrease in the mRNA band 
density by 6.9 ± 1.0% (n = 4)  and 7.7 ± 1.5%  (n = 4) respectively. 
At an 18 h time point (Fig. 7B), a 600 µM MGO treatment led to a pronounced decrease in 
the SUR2B mRNA band density compared to the control value (61.4 ± 3.2%, P < 0.001; n = 4).  
Treatment with lower concentrations of MGO produced a smaller, but significant decrease by 
43.4 ± 6.4% (P < 0.001; n = 4) with 300 µM MGO whereas a 14.4 ± 2.9 % (n = 4) decrease was 
observed with 100 µM MGO.  
At 24 h time point (Fig. 7C), a 600 μM MGO treatment lead to a drastic decrease in the 
levels of SUR2B mRNA by 84.3 ± 1.2% (P < 0.001; n = 4) compared with the control. 
Treatment with lower concentrations of MGO produced a decrease in the SUR2B mRNA band 
density by 68.0 ± 4.4% (P < 0.001; n = 4) with 300 μM and 50.1 ± 7.1% (P < 0.001; n = 4) with 
100 μM MGO. 
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Figure 7. MGO mediates dose dependent decrease in the levels of SUR2B mRNA 
Summary of Net quantitation (NQ) of SUR2B mRNA following MGO treatment (100, 300, and 600 µM). 
A. Exposure time 6 h. B. Exposure time 18 h. C. Exposure time 24 h. ***, P < 0.001; n = 4 experiments.  
 
Taken together, these results suggest that MGO mediated decrease in the levels of 
SUR2B mRNA is dependent on the concentration of MGO. Higher concentration (600 μM) of 
MGO leads to a greater reduction in the density of the SUR2B mRNA band compared with 300 
μM and 100 μM MGO treatment. 
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4.4 SUR2B mRNA levels decrease with an increase in the MGO exposure time 
To determine the time-dependence for the effect of MGO on SUR2B mRNA levels, SUR2B 
mRNA was treated with 300 and 600 µM MGO for 6, 18 and 24 h (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. SUR2B mRNA levels decrease with an increase in the MGO exposure time 
Summary of NQ of SUR2B mRNA at different exposure times (6, 18 and 24 h) following MGO 
treatment. A. MGO concentration, 300 μM. B. MGO concentration, 600 μM. ***, P < 0.001; n = 4 
experiments. 
 
A 300 μM MGO treatment (Fig. 8A) caused a marginal decrease in the levels of SUR2B 
mRNA by 6.9 ± 1.0% (n = 4) after a 6 h MGO exposure, while an exposure to MGO for 18 h and 
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24 h caused graded decreases in the SUR2B mRNA levels by 43.4 ± 6.4% (P < 0.001; n = 4) and 
68.0 ± 4.4% (P < 0.001; n = 4), respectively. 
With a 600 μM MGO treatment (Fig. 8B), a similar pattern of reduction compared to the 300 
μM MGO treatment was observed after 6, 18 and 24 h exposure times.  A  slight decrease in the 
levels of SUR2B mRNA by 7.7 ± 1.5% (n = 4) after a 6 h MGO exposure, while the MGO 
exposure for 18 h and 24 h enhanced the reduction in SUR2B mRNA levels by 61.4 ± 3.2% (P < 
0.001; n = 4) and 84.3 ± 1.2% (P < 0.001; n = 4), respectively. 
4.5 Effect of increasing doses of MGO on Kir6.1 mRNA 
MGO experiments similar to the ones performed on SUR2B mRNAs were also performed on 
the Kir6.1 mRNAs. Kir6.1 mRNA was treated with increasing concentrations (100, 300 and 600 
μM) of MGO for 6, 18 and 24 h time periods.  
Following a 6 h MGO exposure, a marginal decrease in the levels of Kir6.1 mRNA band 
density was observed in response to increasing concentrations of MGO (Fig. 9A). A decrease in 
the band density by 2.4 ± 1.3% (n = 3) was observed with 100 μM MGO treatment. A further 
increase in the MGO concentration did not lead to a further change in the mRNA band density 
(2.4 ± 1.7%, n = 4 with 300 μM and 2.4 ± 0.7%, n = 4 with 600 μM respectively).  
At an 18 h time point (Fig. 9B), a 3.4 ± 1.1 % (n = 4) decrease in the Kir6.1 mRNA band 
compared with the control value was observed following a 100 µM MGO treatment. An increase 
in the MGO dose to 300 and 600 µM led to a slight decrease in the density of Kir6.1 mRNA 
bands by 4.7 ± 1.0% (n = 4) and 5.5 ± 1.3% (n = 4) respectively compared to the control.  
At 24 h time point (Fig. 9C), a 100 μM MGO treatment lead to decrease in the levels of 
Kir6.1 mRNA by 8.5 ± 3.0% (n = 4) compared with the control. Treatment with higher 
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concentrations of MGO produced a decrease in the Kir6.1 mRNA band density by 11.8 ± 2.4% 
(n = 4) with 300 μM and 19.1 ± 2.9% (n = 4) with 600 μM MGO treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Effect of increasing doses of MGO on Kir6.1 mRNA 
Net quantitation (NQ) of Kir6.1 mRNA following MGO treatment (100, 300, and 600 µM). A. Exposure 
time 6 h. B. Exposure time 18 h. C. Exposure time 24 h. n = 4 
 The difference in the Kir6.1 mRNA band densities observed between 100, 300 and 600 
μM MGO treatments was not significant (P > 0.05). These results suggest that MGO does not 
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have an effect on Kir6.1 mRNAs. Increasing the MGO concentrations do not lead to a significant 
change in the Kir6.1 mRNA band density. 
4.6 Effect of MGO on Kir6.1 mRNA at different exposure times 
To determine the time-dependence for the effect of MGO on Kir6.1 mRNA levels, Kir6.1 
mRNA was treated with 300 and 600 µM MGO for 6, 18 and 24 h (Fig. 10). 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 10. Effect of MGO on Kir6.1 mRNA at different exposure times 
Net quantitation (NQ) of Kir6.1 mRNA at different exposure times (6, 18 and 24 h) following MGO 
treatment. A. MGO concentration, 300 μM. B. MGO concentration, 600 μM. n = 4. 
 
A 300 μM MGO treatment (Fig. 10A) caused a marginal decrease in the levels of Kir6.1 
mRNA by 2.8 ± 1.7% (n = 3) after a 6 h MGO exposure, while the an increase in the MGO 
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exposure time to 18 h caused a slight decrease in the Kir6.1 mRNA levels by 4.7 ± 1.0% (n = 4) 
and to 24 h caused a decrease in the mRNA band density by 11.8 ± 2.4% (n = 4). 
With a 600 μM MGO treatment (Fig. 10B), a significantly different pattern in the reduction 
of Kir6.1 mRNA levels compared to 300 μM MGO treatment was not observed, following a 6, 
18 and 24 h exposure times.  A  slight decrease in the levels of SUR2B mRNA by 2.2 ± 0.7% (n 
= 3) after a 6 h MGO exposure, while the MGO exposure for 18 h and 24 h enhanced the 
reduction in Kir6.1 mRNA levels by 5.5 ± 1.3% (n = 4) and 19.1 ± 2.9% (n = 4), respectively. 
The reduction observed in Kir6.1 mRNA band density was not significant (P > 0.05) thereby 
suggesting that MGO does not act on the Kir6.1 mRNA to cause a reduction in Kir6.1 mRNA 
levels.  
Taken together these results suggest that MGO acts on the vascular KATP channels by 
decreasing the expression of KATP channels. MGO acts on the 3’UTR of Kir6.1 mRNA and the 
coding region of the SUR2B mRNA to cause a decrease in the levels of KATP channel mRNAs. 
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5.  DISCUSSION 
In the present study, we have found evidence for the disruption of vascular KATP channels 
with an MGO exposure, and shown the underlying mechanisms.  MGO treatment causes a major 
reduction in the Kir6.1 and SUR2B mRNAs and impairs activity of the KATP channels. 
Remarkably, MGO appears to act on the 3’UTR of the Kir6.1 gene and the coding region of the 
SUR2B gene, leading to mRNA instability and a loss of functional KATP channels in plasma 
membranes.  
Emerging evidence suggests that RCS including MGO play a major role in the development 
of diabetic complications in multiple organs and systems (Bourajjaj et al., 2003). Like ROS, RCS 
are highly reactive, and can modify proteins, DNAs and lipids via Maillard covalent links, 
producing advanced glycation end products (AGEs) (Thornalley et al., 1999). AGEs can cause 
direct damages to intracellular cellular structures and act on extracellular AGE receptors, 
producing more reactive species in the cytoplasm through intracellular signaling systems 
(Brownlee, 2001). When the cellular mechanisms for the detoxification of the RCS are 
overwhelmed by their production, the so-called carbonyl stress takes place. The carbonyl stress 
has been suggested playing even more important role than oxidative stress in the development of 
diabetic vascular complications (Ellis, 2007).  
Although the production of RCS is normally controlled by antioxidants, scavengers and their 
degrading enzymes, there are circumstances when key molecules for the maintenance of 
homeostatic states become defective or dysfunctional, allowing these reactive species to be 
overly produced. Membrane potential appears to be one of such mechanisms (Liu and 
Gutterman, 2002). Depolarization can open the voltage-activated Ca
2+
 channels leading to Ca
2+
 
influx (Anzai et al., 2000; Wray et al., 2005). Since K
+
 channels are the primary regulators of 
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membrane potentials, inhibition of the K
+
 channels results in depolarization and an elevation in 
intracellular Ca
2+
 (Cook et al., 1988). Since several NADPH oxidases for ROS production are 
stimulated by elevated intracellular Ca
2+
 (Brandes et al., 2010; Guzik et al., 2008; Hink et al., 
2001; Zhang et al., 2008), and since RCS and ROS share the antioxidant detoxification systems, 
sustained depolarization may augment the production of these reactive species and aggravate 
oxidative/carbonyl stress.  
The adverse effects of MGO on the vasculature have been studied previously. Most of these 
studies, however, are focused on the molecules of endothelium cells. For example, MGO causes 
impairment of endothelium-dependent vasorelaxation of rat mesenteric arteries in hyperglycemic 
conditions by causing dysfunction of the endothelium (Brouwers et al., 2010). MGO stimulates 
the expression of angiopoietin-2 (Ang-2) protein through the covalent modification of the 
transcriptional repressor mSin3A causing endothelial cell death in mice (Yao et al., 2007). Our 
studies indicate that MGO also acts on K
+
 channels in VSM cells. The dysfunction of VSM cells 
is remarkable as the VSMs regulate vascular tones. The disruption of the key proteins in the 
VSMs for vascular tone regulation tends to impair not only membrane potentials and cellular 
contractility but also the VSM responses to circulating hormones and neurotransmitters as well 
as the local factors released by endothelial cells.  
Oxidative stress and carbonyl stress have a close relationship. Firstly, previous studies have 
shown that the elevated levels of MGO can lead to oxidative stress by inactivation of antioxidant 
enzymes like superoxide dismutase (Desai and Wu, 2008) and glyoxalase (Thornalley, 2003). 
Secondly, MGO can cause mitochondrial dysfunction leading to uncontrolled production of ROS 
in VSMs (Wang et al., 2009), which plays a role in the progression of diabetic vascular 
complications. Thirdly, MGO can promote oxidative stress through AGE receptor (Brownlee, 
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2001) and the NF-κB signaling pathway to produce ROS (Wu and Juurlink, 2002). Moreover, 
several antioxidant detoxification systems are shared by RCS and ROS. An over-production of 
one of the reactive species can compromise the detoxification of the other.  
Though MGO can activate the AGE receptor - NF-κB signaling pathway, we feel that this 
pathway may not be the underlying mechanism for KATP channel inhibition by MGO for two 
reasons: 1) Our in-vitro assay, in which all the signaling components are missing, shows that 
MGO can cause mRNA degradation, indicating a direct action rather than an indirect action via 
signaling pathways. 2) In our previous studies, we have shown that by activating the NF-κB 
signaling pathway lipopolysaccharides augment, rather than suppress, the expression of vascular 
KATP channel mRNAs (Shi et al., 2010). 
Our studies suggest that the vascular KATP channel is indeed inhibited by MGO directly. We 
have found that an exposure to micromolar concentrations of MGO produces a marked 
depression of the KATP currents. Previous studies have shown that plasma MGO levels range 
from 14.2 µM to 33.6 µM in healthy rats (Wang et al., 2004). Several orders of elevation in the 
MGO levels are expected to take place in persistent hyperglycemia (Chang and Wu, 2006). The 
MGO levels may be even higher in local tissues than in the plasma as a result of immediate 
release from cells. Indeed, the MGO levels are as high as 300 µM when measured in cultured 
mammalian cells (Chaplen et al., 1998). The concentrations of MGO used for our study are 
within the physiological range in diabetic conditions. 
Our detailed analysis of the mechanisms underlying the decreases in the Kir6.1 and SUR2B 
transcripts indicates that mRNA instability causes the reduction in the levels of KATP channel 
mRNAs. Interestingly, two completely different mechanisms are in action in the process. MGO 
causes the instability of KATP channel mRNAs by targeting at the 3’UTR of Kir6.1 gene and 
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acting directly on the coding region of SUR2B transcripts. To our knowledge, this is the first 
demonstration of the direct targeting of ion channel mRNA and 3’UTR by MGO. 
Because of the intertwining relationship of ROS and RCS, it is necessary to elucidate 
whether the cellular dysfunction seen in MGO treatment is produced by MGO itself or mediated 
via the associated oxidative stress. Our current studies support that the mRNAs of Kir6.1 and 
SUR2B are directly targeted by MGO, while our previous studies have shown that vascular KATP 
channel protein is directly targeted in oxidative stress conditions through the post-translational 
regulation S-glutathionylation (Yang et al., 2011; Yang et al., 2010). Therefore, the data shown 
in the present studies indicate that MGO has a unique effect on the vascular KATP channels, 
though its adverse consequence on channel inhibition is similar to that of oxidative stress. 
Therefore, carbonyl stress and oxidative stress seem to work synergistically on the vascular KATP 
channels. It is likely that the vascular KATP channels are disrupted in oxidative/carbonyl stress at 
both protein and mRNA levels, resulting in abnormalities in VMS contractility, dysfunction in 
vascular responses to circulating/local vasoactive regulators, and exacerbation of oxidative/ 
carbonyl stress. 
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